Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Effica

March 1, 2030

Company: IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Drug: pembrolizumab
Indication: Metastatic Melanoma; Melanoma; Unresectable Melanoma

Other upcoming events for IOVA

Patent ExpiryPatent/Exclusivity Expiry: PEMETREXED

Patent ExpiryPatent/Exclusivity Expiry: PEMFEXY

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar